Biostage | Regenerations Ahead

Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial

FDA's approval of Biostage's first IND is an extremely important milestone for Biostage as it will transition Biostage into a clinical stage company. >>>

Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
Meet the New Chief Executive
Invest in Biostage and help bring our products to the patients who need them
Biostage has a “breakthrough” technology that is “revolutionary” and would “have considerable clinical use”
Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial
See how Biostage’s Esophageal Implant works to regenerate the esophagus inside the human body
the first ever regeneration of the esophagus in a human cancer patient was done with our product at Mayo clinic and published in JTO Clinical and Research Reports

Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective Treatment

Approximately 1 in 4,000 babies, in the US alone, are born with this congenital defect. Find out how Biostage is working to answer this unmet medical need. >>>

How Biostage Technology Restore Organ Function

Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold. >>>

Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial

Esophageal Atresia:A Life-Threatening Conditionthat Demands Effective Treatment

How Biostage Technology Restore Organ Function

Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective Treatment